CJC-1295 without DAC 10mg

Description

CJC-1295 Without DAC Technical Overview

CJC-1295 without DAC is a commercial designation commonly applied to Modified GRF(1–29), a synthetic analogue of the N-terminal 29-amino-acid region of growth hormone-releasing hormone.

The compound contains modifications intended to influence peptide stability while retaining GHRH receptor-associated activity.

Unlike CJC-1295 with DAC, this preparation does not contain an albumin-binding Drug Affinity Complex.

Compound Specifications

Storage and Handling

• Follow manufacturer-validated conditions.
• Protect from moisture, light, and contamination.
• Use appropriate laboratory peptide handling procedures.

Lyophilized Format

Modified GRF(1–29) may be supplied in lyophilized form. Actual stability depends on formulation.

Research Use Disclaimer

Modified GRF(1–29) is not FDA-approved for human therapeutic use. Not intended for human or veterinary administration.

Frequently Asked Questions

What Is CJC-1295 Without DAC?

A commercial name associated with Modified GRF(1–29).

How Many Amino Acids Does It Contain?

29.

What Receptor Does It Target?

GHRHR.

How Does It Differ From CJC-1295 With DAC?

It lacks the albumin-binding modification.

Research Overview

Modified GRF(1–29) is investigated in GHRH receptor and peptide stability research.

GHRHR Signaling

Experiments study receptor activation and cellular signaling.

Peptide Stability

Research examines changes in stability associated with amino acid substitutions.

Endocrine Research

Studies investigate growth hormone-releasing hormone pathways.

Research Applications

References

1. Modified GRF(1–29) Research — PubMed.

Certificate of Analysis (COA)

Documentation should confirm modified peptide identity, purity, and content.

Peptide Lives